Physician profile
Brian Lynn Eddy
NPI 1770692568
$2,367.52
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,036 · 2020: $317 · 2023: $14.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $226.19 | 2019-2020 | |
| Pfizer INC. | $193.44 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $189.51 | 2019-2020 | |
| Janssen Biotech, INC. | $172.72 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $166.98 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $154.49 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $127.35 | 2019-2020 | |
| Eisai INC. | $125.63 | 2019-2020 | |
| Abbvie INC. | $122.87 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $106.34 | 2019-2020 | |
| Genzyme Corporation | $79.83 | 2019-2020 | |
| Incyte Corporation | $73.54 | 2019-2020 | |
| Amgen INC. | $66.92 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $48.80 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.72 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $41.07 | 2019 | |
| Clovis Oncology, INC. | $40.71 | 2019 | |
| Array Biopharma INC | $38.71 | 2019 | |
| Celgene Corporation | $34.68 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $34.42 | 2019 | |
| Seagen INC. | $29.65 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $26.61 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $24.49 | 2019 | |
| Sandoz INC. | $23.22 | 2019 | |
| Puma Biotechnology, INC. | $19.11 | 2019 | |
| Astellas Pharma US INC | $18.80 | 2019 | |
| Mylan Institutional INC. | $18.73 | 2019 | |
| Agios Pharmaceuticals, INC. | $17.52 | 2020 | |
| Tesaro, INC. | $16.35 | 2019 | |
| Medtronic, INC. | $14.84 | 2023 | Intellis Adaptivestim |
| Rigel Pharmaceuticals, INC. | $13.77 | 2019 | |
| Lilly USA, LLC | $12.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.91 | 2019 | |
| Verastem, INC. | $11.88 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.67 | 2019 | |
| Glaxosmithkline, LLC. | $11.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Eddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.